Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes
Primary Purpose
Type 2 Diabetes
Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
ISIS-APOCIIIRX
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria:
- BMI >/= 25 to </= 40 kg/m2
- Type 2 Diabetes Mellitus and on a stable dose of metformin
- Hypertriglyceridemia
Exclusion Criteria:
- Significant abnormalities in medical history, clinical examination or clinical testing
- Use of oral anti-diabetic medication other than metformin within 3 months prior to dosing
- History of outpatient insulin use for more than 2 weeks in the last year
Sites / Locations
- Profil Institute for Clinical Research
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
ISIS-APOCIIIRX
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Total apoC-III
The effect of treatment with ISIS ISIS-APOCIIIRX or Placebo on fasting total apoC-III levels.
Secondary Outcome Measures
Insulin Sensitivity
Change from baseline in insulin sensitivity
Full Information
NCT ID
NCT01647308
First Posted
July 19, 2012
Last Updated
January 13, 2022
Sponsor
Ionis Pharmaceuticals, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01647308
Brief Title
Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes
Official Title
A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Investigate the Effects of ISIS 304801 Lowering of ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
January 2022
Overall Recruitment Status
Terminated
Why Stopped
The study was terminated for business planning purposes. Assessments of APOCIIIRx in this population will be explored in a larger efficacy study
Study Start Date
July 2012 (undefined)
Primary Completion Date
January 2014 (Actual)
Study Completion Date
March 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ionis Pharmaceuticals, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the effects of ISIS ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects with Type 2 Diabetes on stable treatment with metformin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
15 (Actual)
8. Arms, Groups, and Interventions
Arm Title
ISIS-APOCIIIRX
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
ISIS-APOCIIIRX
Intervention Description
3 doses of ISIS ISIS-APOCIIIRX on alternate days during the first week and then once-weekly doses for 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
Primary Outcome Measure Information:
Title
Total apoC-III
Description
The effect of treatment with ISIS ISIS-APOCIIIRX or Placebo on fasting total apoC-III levels.
Time Frame
91 Days
Secondary Outcome Measure Information:
Title
Insulin Sensitivity
Description
Change from baseline in insulin sensitivity
Time Frame
Day 92
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
BMI >/= 25 to </= 40 kg/m2
Type 2 Diabetes Mellitus and on a stable dose of metformin
Hypertriglyceridemia
Exclusion Criteria:
Significant abnormalities in medical history, clinical examination or clinical testing
Use of oral anti-diabetic medication other than metformin within 3 months prior to dosing
History of outpatient insulin use for more than 2 weeks in the last year
Facility Information:
Facility Name
Profil Institute for Clinical Research
City
Chula Vista
State/Province
California
ZIP/Postal Code
91911
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
27271183
Citation
Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM. Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. Diabetes Care. 2016 Aug;39(8):1408-15. doi: 10.2337/dc16-0126. Epub 2016 Jun 6.
Results Reference
derived
Learn more about this trial
Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes
We'll reach out to this number within 24 hrs